Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsOscar Health NK1 Antiemetic Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentOscar HealthPolicy CG103

    Antiemetics - Substance P/Neurokinin 1 (NK1) Antagonist (i.e., Fosaprepitant or Aprepitant Products) - Medical Benefit Preferred Physician-Administered Drug Exceptions Criteria

    Customize your policy alerts

    Sign up for Oscar Health Policy CG103 alerts

    Get alerted when Policy CG103 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization exceptions for non-preferred physician-administered Substance P/neurokinin 1 antagonist antiemetics under the medical benefit. It applies when a clinical exception to the Plan's preferred products is needed.

    Policy Summary
    PayerOscar Health
    PolicyAntiemetics - Substance P/Neurokinin 1 (NK1) Antagonist Medical Benefit Preferred Physician-Administered Drug Exceptions Criteria
    Policy CodePolicy CG103
    Change TypeNo material change
    Effective DateN/A
    Last ReviewJan 1, 2026
    Next Review DateN/A
    Key ActionSubmit supporting clinical documentation when requesting an exception to use a non-preferred product.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    4Products listed in the medical preferred drug table
    ALLRequired exception criteria
    1 cycleSingle-cycle chemotherapy authorization
    6 months

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Chronic chemotherapy authorization
    3 monthsShortage-based initial authorization
    4Applicable billing codes

    Coverage Criteria

    Non-preferred product exception criteria

    Coverage for a non-preferred product will be provided when the member meets ALL of the following criteria.

    Non-preferred product exception

    • Qualifying exception circumstance

      • Preferred product unavailable: There is a drug shortage or unavailability of the preferred product.
      • Specific non-preferred product required: The member requires a specific non-preferred product because of documented hypersensitivity to specific excipients in a preferred product, documented incompatibility with the concurrent chemotherapy regimen, or specific infusion requirements that cannot be achieved with a preferred product.
      • Preferential evidence or guideline support: Clinical evidence and/or current treatment guidelines, such as NCCN, support preferential use of the requested product over all preferred products for the therapy regimen.
      • State prerequisite-trial prohibition: The request is for cancer treatment in a state prohibiting prerequisite trials under applicable regulations.
    • Supporting clinical documentation: Clinical documentation is provided to support the exception request, such as notification of drug shortage or unavailability, detailed documentation of a hypersensitivity reaction, compatibility data when applicable, or the specific reason the preferred product cannot be used.

    Experimental, investigational, or not medically necessary uses

    Non-preferred products are not covered for uses that are experimental, investigational, or not medically necessary.

    Non-covered use: The requested use is outside FDA-approved labeling or is not supported by current medical evidence and standards of care; involves a non-FDA-approved indication or off-label use without sufficient evidence supporting safety and efficacy; uses doses exceeding the FDA-approved label or clinical practice guidelines without sufficient evidence supporting safety and efficacy; is not required for treatment or management of the member's medical condition; is not aligned with generally accepted medical practice; or is primarily for the convenience of the member, family, or provider.

    The listed non-approved indications are not all-inclusive.

    Oscar does not cover non-preferred products when used for experimental, investigational, or medically unnecessary indications. Excluded uses include unsupported non-FDA-approved indications or off-label use, doses exceeding the FDA-approved label or clinical practice guidelines without sufficient evidence of safety and efficacy, treatment not required to manage the member’s condition, use outside generally accepted medical practice, or use primarily for convenience.

    Use of a non-preferred product is not medically necessary when it is not required to treat or manage the member’s medical condition, is not aligned with generally accepted medical practice, or is primarily for the convenience of the member, family, or provider. An indication may also be considered not medically necessary when it is clinically inappropriate based on factors such as age, dosage, frequency, duration of therapy, site of administration, or contraindication.

    Applicable Billing Codes

    CPT/HCPCS Codes considered medically necessary if criteria are metHCPCSCovered
    J0185Cinvanti Injection, aprepitant, 1 mg
    J1434Focinvez Injection, fosaprepitant (focinvez), 1 mg
    J1453Emend (fosaprepitant dimeglumine) Injection, fosaprepitant, 1 mg
    J1456fosaprepitant dimeglumine Injection, fosaprepitant (teva), not therapeutically equivalent to J1453, 1 mg

    Authorization and Submission Guidance

    Prior Authorization

    Non-Preferred Product Exception Review

    Requests for a non-preferred product are reviewed through prior authorization to determine whether a clinical exception can be made under the Plan's Medical Benefit Preferred Drug Exceptions Criteria.

    • The program applies to members requesting a non-preferred product.
    • Approval may be considered when the member cannot use or has not benefited from the Plan's preferred product(s).
    Prior Authorization

    Authorization Submission Route

    Submit authorization requests through the applicable review entity and route based on the indication.

    • Oncology: EviCore review; submit through the provider portal at www.evicore.com or call 855-252-1118.
    • Non-oncology: Oscar review; use the authorization tool at provider.hioscar.com, call 855-672-2755, or fax the form from www.hioscar.com/forms to 800-540-2406.

    Policy Background

    This policy addresses Substance P/neurokinin 1 (NK1) antagonist antiemetics administered under the medical benefit, including fosaprepitant and aprepitant products. It applies to requests for non-preferred products used in chemotherapy-related treatment regimens, including prevention or management of chemotherapy-associated nausea and vomiting, when a documented clinical exception to the Plan’s preferred physician-administered products is needed.

    Key Definitions

    Compendia
    DefinitionSummaries of drug information and medical evidence.
    PurposeUsed to support decision-making about the appropriate use of drugs and medical procedures.
    ExamplesExamples include American Hospital Formulary Service Drug Information, Elsevier Clinical Pharmacology, NCCN Drugs and Biologics Compendium, Thomson Micromedex DrugDex, and USP-NF.
    Contraindication
    DefinitionA pre-existing condition or factor.
    Effect on treatmentThe condition or factor precludes use of a drug.
    Reason

    Initial Non-preferred Product Exception

    Initial non-preferred product exception

    Initial coverage of a non-preferred product requires ALL exception criteria to be satisfied.

    Initial exception authorization

    • Qualifying exception circumstance: The member has a qualifying reason to use the requested non-preferred product: preferred-product shortage or unavailability; documented product-specific clinical need; clinical evidence or current treatment-guideline support for preferential use of the requested product over all preferred products; or cancer treatment in a state prohibiting prerequisite trials under applicable regulations.
    • Supporting clinical documentation: The provider submits clinical documentation supporting the exception request, such as shortage or unavailability notification, detailed hypersensitivity documentation, compatibility data when applicable, or the specific reason the preferred product cannot be used.

    Authorization Duration and Continuation

    Authorization duration and continuation

    When the prior authorization criteria are met, authorization duration depends on the treatment context.

    Authorization duration

    • Single-cycle chemotherapy: The requested product is authorized for one-time treatment of a single chemotherapy cycle.1 cycle
    • Chronic chemotherapy regimen: The requested product is authorized for a chronic chemotherapy regimen.Up to 6 months
    • Drug shortage or unavailability: The requested product is initially authorized because of a drug shortage or unavailability.

    Preferred Product First

    StepPreferred-product requirementQualifying exception
    1Try the Plan's preferred physician-administered NK1 antagonist product first when it is safe and effective.An exception may be supported by documented trial and failure, inadequate response, intolerance, or contraindication to all applicable preferred drugs; risk of poor response; or documentation that the member is not a candidate for preferred drugs.
    Policy Summary
    PayerOscar Health
    PolicyAntiemetics - Substance P/Neurokinin 1 (NK1) Antagonist Medical Benefit Preferred Physician-Administered Drug Exceptions Criteria
    Policy CodePolicy CG103
    Change TypeNo material change
    Effective DateN/A
    Last ReviewJan 1, 2026
    Next Review DateN/A
    Key ActionSubmit supporting clinical documentation when requesting an exception to use a non-preferred product.
    SourceLink
    On This Page
    Coverage CriteriaApplicable Billing CodesAuthorization and Submission GuidancePolicy BackgroundKey DefinitionsInitial Non-preferred Product ExceptionAuthorization Duration and ContinuationPreferred Product First
    Step Therapy

    Preferred-Product Prerequisite

    Preferred medications generally must be tried first when they are considered safe and effective by the treating provider. A non-preferred product may be approved when the member has tried and failed, has an inadequate response or intolerance, or cannot use all applicable preferred products.

    • Documented exceptions may include risk factors for poor response to a preferred product.
    • An exception may also apply when the member is not a candidate based on the member's condition, individual needs, treatment history, or accepted standards of medical practice.
    Documentation Required

    Exception-Supporting Documentation

    Support a non-preferred product exception request with clinical documentation showing why the preferred product cannot be used or why the requested product is needed.

    • Drug-shortage or unavailability notification.
    • Specific details of a hypersensitivity reaction, including incompatibility with an excipient when applicable.
    • Compatibility data for a concurrent chemotherapy regimen when applicable.
    • Specific infusion requirements that cannot be achieved with the preferred product.
    • Specific reason(s) why the preferred product cannot be used.
    Documentation Required

    General Clinical and Trial Documentation

    Provide up-to-date clinical and treatment records to support the request, including documentation of diagnoses, prior therapy, and relevant medical necessity.

    • Current chart notes, relevant test results, and/or relevant imaging reports.
    • Prescription claims records and/or prescription receipts supporting prior trials of alternative or preferred products.
    • For intolerance, document the specific intolerable effects and their impact on quality of life, adherence, or overall health.
    • For contraindication, document the pre-existing condition or factor that creates a risk of harm.
    Denial Risk

    Exception Criteria Not Met

    Coverage for a non-preferred product requires at least one qualifying exception circumstance and clinical documentation supporting that circumstance. Requests are at risk for denial when the required exception criteria are not demonstrated.

    • No documented shortage or unavailability of the preferred product.
    • No documented hypersensitivity, chemotherapy incompatibility, or specific infusion requirement preventing use of the preferred product.
    • No evidence that current clinical evidence or treatment guidelines support preferential use of the requested product over all preferred products.
    • No applicable regulatory basis, such as a state prohibition on prerequisite trials for cancer treatment.
    • Required clinical documentation is missing or does not support the exception.
    Denial Risk

    Experimental, Investigational, or Medically Unnecessary Use

    The Plan does not cover non-preferred products used for experimental, investigational, or medically unnecessary indications, including uses outside FDA-approved labeling or unsupported by current medical evidence and standards of care.

    • Non-FDA-approved or off-label use without sufficient evidence of safety and efficacy.
    • Doses exceeding FDA-approved labeling or clinical practice guidelines without sufficient supporting evidence.
    • Use not required to treat or manage the member's medical condition.
    • Use not aligned with generally accepted medical practice.
    • Use primarily for the convenience of the member, family, or provider.
    • Indications involving clinically inappropriate age, dose, frequency, duration, site of administration, or contraindication.
    Denial Risk

    Preferred Product Remains Appropriate

    A non-preferred product remains subject to denial when the member's record does not demonstrate failure, inadequate response, intolerance, contraindication, or another qualifying reason that makes the preferred product inappropriate.

    • Preferred products are selected based on clinical effectiveness, safety, FDA approval, and treatment guidelines.
    • Documented trial and failure, inadequate response, intolerance, or contraindication must apply to all preferred products, as applicable.
    • A risk factor for poor response or lack of candidacy must be supported by the member's condition, individual needs, treatment history, or accepted standards of medical practice.
    Use is precluded because of risk of harm.
    Intolerance
    DefinitionThe inability to tolerate or endure a medication or treatment.
    Possible causeDifficult or harmful side effects, reactions, or hypersensitivities.
    Clinical impactThe effects negatively impact quality of life, ability to adhere, or overall health.
    Documentation
    DefinitionWritten information used to support diagnoses or prior trials of alternatives.
    Clinical recordsMay include up-to-date chart notes, relevant test results, and relevant imaging reports supporting diagnoses.
    Pharmacy recordsMay include prescription claims records and prescription receipts supporting prior trials of alternatives.
    Experimental or Investigational
    DefinitionA procedure, drug, or device that has not been proven effective.
    Regulatory statusIt may also refer to a procedure, drug, or device that has not been approved by the appropriate regulatory bodies.
    ScopeThe term applies to procedures, drugs, and devices.
    Medical Benefit Preferred Drug Exceptions Criteria
    DefinitionPlan requirements that must be met for a non-preferred drug to be approved for coverage.
    Preferred-drug trialRequirements may include trying preferred drugs first.
    Failure requirementRequirements may include trial and failure of preferred drugs before approval of the non-preferred drug.
    3 months

    The authorization may be extended based on continued documentation of the shortage or unavailability. If the shortage or unavailability resolves before the authorization period ends, transition to the preferred product may be required at the next authorization period.